PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijnmHomeCurrent issueInstructionsSubmit article
 
Indian J Nucl Med. 2010 Apr-Jun; 25(2): 49–52.
PMCID: PMC3003283

Estimation of effective half life of clearance of radioactive Iodine (131I) in patients treated for hyperthyroidism and carcinoma thyroid

Abstract

Background

In medical applications of radioisotopes, for calculations of whole body doses and radiation safety applications, there is a need to estimate radioactive body burden. Local recommendations in Oman stipulate the need for hospitalization of patients treated for radioactive-iodine (131 I) with activities above 400 MBq.

Materials & Methods:

A study of body burden estimation from sequentially measured exposure rates from patients treated for carcinoma thyroid and hyperthyroidism was undertaken. A digital auto-ranging beta gamma survey instrument calibrated for measurement of exposure rates is used in this study.

Results:

The mean measured exposure rates at 1 m in μSv/h immediately after administration and at 24 h intervals are used for estimation of effective half time of clearance of administered activity. For patients with post-operative thyroid carcinoma, the variation of body burden with time post-administration indicated tri-exponential clearance pattern, with T½eff values 14.4 h, 22 h, and 41.3 h. For patients treated for thyrotoxicosis, the body burden showed slow delayed clearance with a T½eff – 111.4 h, and exposure rates did not show appreciable fall off after 48 h.

Keywords: Carcinoma thyroid, body burden, effective half life, iodine-131

INTRODUCTION

Treatments for ablation of functioning thyroid for management of hyperthyroidism and for the elimination of post-surgical residual thyroid tissues in differentiated carcinoma of thyroid by administration of radioactive iodine (RA131I) are well-established procedures in clinical nuclear medicine. The administered radioactive iodine is absorbed in the functioning thyroid tissue and gets eliminated mainly from the bowel, resulting in whole body dose in addition to being taken up in the glandular tissues of thyroid. The effective half life for clearance of radioactive body burden for normal human subjects is about 5.5 days (about 132 h) which is useful in health physics applications, to calculate the radiation dose received by the thyroid and total body, from the beta and gamma emissions originating from the radioactive iodine. In case of patients treated for carcinoma thyroid, because of surgical removal of thyroid tissues, elimination of administered I-131 radioactivity clears at a faster rate, thereby allowing treatments with large amounts of I-131 as high as 1.85 GBq to 5.5 GBq (50-150 mCi).

The assessment of external radiation exposures from patients at known geometry using radiation monitors is one of the accepted standard methods for estimation of radioactive body burden.[15] Present regulations in Oman[6] indicates the need for hospitalization of patients above 400 MBq administered activities of RA131I. We have only two isolation rooms connected with delay tank facility for I-131 treatments. This led to a waiting list for treatments of thyroid cancers in the oncology center. A recent report from Oman[7] has indicated that with good radiation safety instructions to patients and relatives, thyrotoxic patients may be treated as outpatients, provided the patient is physically and mentally fit enough to comply with given instructions. To address the isolation of Omani patients treated with RA131I in the wards, justifying out-patient treatments for patients with thyrotoxicois and making necessary recommendations regarding their retention period of Ca. thyroid patients, we have analyzed the records of external exposure rates measured from patients who underwent radio-iodine therapy both for differentiated carcinoma thyroid and thyrotoxicosis.

MATERIALS AND METHODS

Patients

The patients who received RA131I were referred from endocrinology department of the Royal Hospital based on accepted protocols [Table 1]. Patients were accepted for their treatments after obtaining informed consent after these patients were properly explained by the nuclear medicine consultants about the procedure, and possible associated risks. The patients treated during the period 2006 to 2009 were taken up for the study.

Table 1
Standard operating procedure of nuclear medicine department

Administration of RA131I

The radioactive iodine is in the form of capsules supplied by GE Healthcare, Amersham, UK. The administrations were carried out on Mondays, and the activities were ordered with reduced activities with reference dates on Thursdays. The radioactive strengths (activity) of the capsules were assayed in Mark V, CalRad Isotope Calibrator (Model 34-164, Nuclear Associates, USA) immediately after arrival of consignment. The containers are labeled with suitable identifications, and activity certificates are prepared in the department. The work flow relating to RA131I administrations followed in the department is shown in Table 2.

Table 2
Work Flow regarding radioiodine administration

Measurement of exposure rates

Radiation monitoring is carried out using a wide range beta gamma survey meter, auto-ranging with digital reading facility made up of built-in ionization chamber (Inovision, USA). This is hand held type with measuring range 0.1 μSv/h to 100 Sv/h. The exposure rates are measured at 5 cm distance at stomach and neck levels; and at 1 m and 2 m distances with patient sitting on the hospital bed. These measurements are recorded on the first and subsequent days till discharging the patient. Patients are allowed to go home when their exposure rates fall below 10μSv/h (1.0 mR/h) at 1 m distance. This may correspond to retention of residual body burden of about 170 MBq (4.6 mCi).

RESULTS

Table 3 shows the number of patients who received treatments for Ca. thyroid and thyrotoxicosis along with the activities of Ra131I administered. The mean activities administered were 4.19 GBq and 574.7 MBq for these groups of patients respectively. Table 4 shows the measured mean exposure rates and standard deviation. The number of patients is indicated in brackets. The semi-log plot of these mean exposure rates [Figure 1] gave two distinct patterns of clearance of radioactive body burdens. For patients with post-operative Ca.thyroid, the variation of body burden with time post-administration indicated a tri-exponential pattern. The three slopes of the plots yielded T½eff values 14.4 h, 22.0 h and 41.3 h. For patients treated for thyrotoxicosis, the body burden showed slow rate of clearance with a T½eff =111.4 h, and the exposure rate at 1 m did not show appreciable change after 48 h [Table 4].

Table 3
Details of administered activity
Table 4
Measured Exposure rates in μSv/h at 1m from patients post administration of I-131
Figure 1
Patterns of Clearance of body burden with administration of RA131I

DISCUSSION

Our mean exposure rates at 1 m immediately following administration of activity were 88.0 μSv/h (SD 37.6) and 14.9 μSv/h (SD 6), respectively, for the Ca. thyroid and thyrotoxic patients. The results of 1 m exposure rates for thyrotoxic patients 23.4 ±; 6.3 μSv/h as reported by Ibtisaam and Bererhi[7] are of the same magnitude. The mean activity of thyrotoxic patients is 574.7 MBq in the present work, to the mean activity of 609.8 MBq reported by these authors. For the patients with thyrotoxicosis, the mean half time of clearance of body burden in our work is T½eff = 111.4 h which is of the order of magnitude quoted by Meredith and Massey,[8] which is 5.5 days (about 136 h).

In our study, the exposure rate at 1 m is averaged over measured values and represented along with the range. This is because of many variables, such as administered activities [Figure 2], various age groups of patients ranging from 18 to 73 years, both sex and different patient weights. For health physics purposes, these values still give an estimate of the risk involved in terms of radiation levels encountered during isolation of these patients.

Figure 2
Details of administered activities in Ca Thyroid patients

In the Ca. thyroid patients in the present work, an estimated effective half time of clearance of 14.4 h for body burden is in good agreement with the earlier reported value 11.2-15.4 h[5] in Indian population, and the values reported by Barrington et al,[4] viz. 9.4 h, 13.4 h and 12 h. Thomas et al,[1] compared three methods of body burden estimation viz. 1) urine assay 2) prediction based on a pre-therapy diagnostic work up method using 74 MBq (2 mCi) 3)external exposure rate measurements during actual treatments. They opined that direct external exposure rate surveys showed the potential for being an accurate, reliable and relatively safe method of monitoring patient’s I-131 body burden. From Table 4, it is clearly seen that the exposure rate around the patient treated for thyrotoxicosis remains unchanged after 48 h, seldom reaching the value of 10 μSv/h (1 mR/h) at 1 m because of retention of activity by toxic thyroid.

The Nuclear Regulatory Commission (NRC) specifies patient’s discharge when the body burden falls below about 1100 MBq (30 mCi). However, based on the social and cultural reasons and living conditions in their home, 1100 MBq I-131 appears to be a higher activity limit in Oman. A lower limit of 400 MBq for the patients to be hospitalized (as per prevailing MOH recommendations)[6] will indicate need for hospitalization of all the patients treated for thyrotoxic disorders (above 370MBq). This will make the need for creation of more isolation rooms, which is not practical. Our body burden measurements in thyrotoxic patients treated in the last four years clearly indicate an effective half time of clearance around 114 h (about five days) and no further clearance after 48 h post administration. In this context, it appears that there is no justification in hospitalizing these thyrotoxic patients post administration of I-131 to reduce their body burden to permissible limits, with the presence of healthy thyroid, concentrating bulk of administered activities because of high uptakes. Hospitalization of a few patients for thyrotoxicosis treatments may therefore be selectively restricted to some cases who have infant children around or many inmates living in small homes, justifying reduction of public exposures to permissible levels.

Acknowledgments

Permission from Director General, Royal Hospital, for publication of above work is gratefully acknowledged.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

REFERENCES

1. Thomas SR, Maxon HR, Fritz KM, Kereiakes JG, Connell WD. A comparison of methods for assessing patient body burden following I-131 therapy for thyroid cancer. Radiology. 1980;137:839–42. [PubMed]
2. Castronovo FP, Beh RA, Veilleux NM. Dosimetric considerations while attending hospitalized I-131 therapy patients. J Nucl Med Tech. 1983;10:157–60.
3. Samuel AM, Rajashekharrao B. Radioiodine therapy for well differentiated thyroid cancer. A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med. 1994;35:1944–50. [PubMed]
4. Barrington SF, Kettle AG, O’Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation doserates from patients receiving Iodine-131 therapy for carcinoma thyroid. Euro J Nucl Med. 1996;23:123–30. [PubMed]
5. Ravichandran R, Supe SS, Jayasree U, Devaru S. Measurement of the radioactive body burden in patients receiving Iodine-131 treatments for carcinoma of the thyroid. Euro J Nucl Med. 1997;24:464. [PubMed]
6. Arunkumar LS. Guidelines on I-131 therapeutic uses. Recommendations from Medical Physics and Radiation Protection Service, DGEA. Sultanate of Oman: Ministry of Health; 2006.
7. Ibtisaam AM, Bererhi H. Radiation exposure levels in family members of Omani patients with thyrotoxicosis treated with radio-iodine (I-131) as outpatients. SQU Med J. 2009;9:148–52. [PMC free article] [PubMed]
8. Meredith WJ, Massey JB. 3rd ed. London: John Wright and Sons Ltd; 1977. Fundamental Physics of Radiology; pp. 420–3.

Articles from Indian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India are provided here courtesy of Wolters Kluwer -- Medknow Publications